AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33740052
Drug: Mannitol excretion
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol excretion at 6 months
Trial: 33740205
Drug: Omission of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omission of surgery in complete responders to neoadjuvant chemotherapy
Trial: 33740902
Drug: Eptinezumab 300
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eptinezumab 300 mg by 30-min intravenous administration every 12 weeks for up to 8 doses
Trial: 33740903
Drug: ADHD- (medication-naïve)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADHD- (medication-naïve)
Trial: 33741071
Drug: Theory-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theory-based intervention consisting of an online video and patient recall process for medication reviews.
Trial: 33741296
Drug: Eribulin 1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin 1.1 mg/m² in combination with avelumab
Trial: 33741296
Drug: Avelumab (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab (fixed dose)
Trial: 33741317
Drug: TAK-062 (100-900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-062 (100-900 mg)
Trial: 33741442
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan (SG) 8, 10, 12, or 18 mg/kg on days 1 and 8 of 21-day cycles until disease progression or unacceptable toxicity
Trial: 33741467
Drug: Deep regional
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep regional hyperthermia scheduled twice weekly
Trial: 33741641
Drug: Gastric per-oral
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric per-oral endoscopic myotomy (G-POEM)
Trial: 33741670
Drug: Hypothetical participation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothetical participation in an early phase CAR-T cell therapy trial
Trial: 33742104
Drug: Tumor genomic
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor genomic profiling and targeted agents
Trial: 33742208
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplement with social and behavior change communication intervention
Trial: 33743073
Drug: Metronomic oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic oral vinorelbine (VRL; 30 mg/day)
Trial: 33743128
Drug: Intraoperative photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative photodynamic therapy (PDT) after 5-aminolevulinic acid (5-ALA) administration and maximal resection
Trial: 33743171
Drug: Standard-dose P-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose P-T (4.5 g every 6 h)
Trial: 33743171
Drug: High-dose P-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose P-T (up to 6.75 g or 9 g every 6 h)
Trial: 33743171
Drug: High-dose P-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose P-T
Trial: 33743238
Drug: Onasemnogene abeparvovec
RxNorm normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Onasemnogene abeparvovec (1·1×10^14 vg/kg) administered as a one-time intravenous infusion.
Trial: 33743541
Drug: Combination antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antiretroviral therapy (cART) for HBV-HIV co-infection
Trial: 33743801
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose vitamin D3 (400 IU daily for 24 weeks)
Trial: 33743801
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin D3 (3200 IU daily for 12 weeks then 800 IU daily for 12 weeks)
Trial: 33743801
Drug: Biochemical monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biochemical monitoring (25-hydroxyvitamin D, corrected calcium, albumin, parathyroid hormone, hepcidin, other vitamin D metabolites, iron studies, C-reactive protein)
Trial: 33745032
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CHK1 inhibitor prexasertib (105 mg/m2) and anti-PD-L1 antibody LY3300054
Trial: 33745032
Drug: Anti-PD-L1 antibody
RxNorm normalized name: Protease-activated anti-pd-l1 antibody prodrug cx-072
DrugBank: Pacmilimab (DB18873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-L1 antibody LY3300054 (Arm A)
Trial: 33745032
Drug: CHK1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHK1 inhibitor prexasertib (Arm B)
Trial: 33746047
Drug: Recent cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent cytotoxic chemotherapy
Trial: 33746047
Drug: Specific anticancer
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific anticancer therapies (e.g. R-CHOP, platinum combined with etoposide, DNA methyltransferase inhibitors)
Trial: 33746446
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both DIA and CCE
Trial: 33748440
Drug: Selumetinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (50 mg orally twice daily) starting 7 days prior to thoracic radiotherapy and continuing during radiotherapy (6-6.5 weeks; 60-66 Gy/30-33 fractions)
Trial: 33748842
Drug: Prophylactic ACEi
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic ACEi treatment
Trial: 33748921
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab 600 mg fixed dose plus intravenous pertuzumab (loading dose: 840 mg/kg; maintenance: 420 mg/kg) and docetaxel (≥ 6 cycles; initial dose 75 mg/m2)
Trial: 33748921
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab plus intravenous pertuzumab and docetaxel
Trial: 33749049
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) 1,000 mg/m²
Trial: 33749049
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) + Metformin
Trial: 33749049
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) + Melatonin + Metformin
Trial: 33749616
Drug: Home-Based Exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-Based Exercise Therapy (HBET) using wearable technology and elastic band resistance exercises, 3 walking sessions and 2 resistance exercise sessions per week for 4 weeks.
Trial: 33749616
Drug: Home-Based Exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-Based Exercise Therapy (HBET)
Trial: 34637151
Drug: Abrocitinib 200
RxNorm normalized name: abrocitinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrocitinib 200 mg oral dose
Trial: 33750196
Drug: Last prior
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Last prior therapy
Trial: 33750432
Drug: XAV-19 (polyclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XAV-19 (polyclonal humanized anti-SARS-CoV2 antibodies) administered intravenously, dosage and duration not specified.
Trial: 33750454
Drug: ED-initiated buprenorphine
RxNorm normalized name: Ed-APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ED-initiated buprenorphine (BUP) with referral for treatment of OUD
Trial: 33752251
Drug: Remote intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remote intervention including three weekly phone calls and regular follow-up calls.
Trial: 33753433
Drug: Serological testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serological testing for anti-hepatitis A virus, hepatitis B surface antigen, hepatitis B surface and core antibody
Trial: 33753457
Drug: Pacritinib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacritinib combined with Sirolimus and Low-Dose Tacrolimus (PAC/SIR/TAC)
Trial: 33753457
Drug: Pacritinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacritinib (100 mg daily, 100 mg twice daily, 200 mg twice daily)
Trial: 33753460
Drug: Quarterly syndromic
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quarterly syndromic diagnosis and treatment for STI, HIV testing, peer-led counselling and support, provision of condoms and lubricants.
Trial: 33754187
Drug: Niraparib 200
RxNorm normalized name: niraparib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 200 mg with AAP
Trial: 33754187
Drug: Niraparib 300
RxNorm normalized name: niraparib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 300 mg with AAP
Trial: 33754187
Drug: Niraparib 200
RxNorm normalized name: niraparib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 200 mg with apalutamide
Trial: 33754317
Drug: Moderate/highly anticholinergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate/highly anticholinergic medications
Trial: 33754642
Drug: Ibrutinib (840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (840 mg)
Trial: 33754642
Drug: Ibrutinib (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (420 mg and 840 mg)
Trial: 33755155
Drug: Dried serum
RxNorm normalized name: peptone,dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried serum spots (DSS) with an oral dose of 0.4 mg [13C10]retinyl acetate
Trial: 33756515
Drug: Volumetric modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volumetric modulated arc therapy (VMAT)
Trial: 33757307
Drug: Guideline-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed therapy
Trial: 33757307
Drug: β-blocker and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blocker and device therapies
Trial: 33757459
Drug: Nivolumab/ipilimumab combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab/ipilimumab combination therapy (Ipilimumab administered once on Day 1; Nivolumab administered on Day 1 and Day 22 for a total of two 21-day cycles).
Trial: 33757581
Drug: Transcranial rotating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial rotating permanent magnet stimulator (TRPMS) treatment, 10 sessions of 40 minutes each.
Trial: 33757788
Drug: Adherent patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherent patients (≥80% drug intake)
Trial: 33757788
Drug: Non-adherent patients
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adherent patients (<80% drug intake)
Trial: 33757788
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with ≥9 co-medications
Trial: 33757987
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CDK4/6 inhibitor palbociclib, immune checkpoint inhibitor pembrolizumab, and aromatase inhibitor letrozole (palbo+pembro+AI)
Trial: 33757987
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitor pembrolizumab and aromatase inhibitor letrozole (pembro+AI)
Trial: 33762025
Drug: Beta-lactam therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-lactam therapeutic drug monitoring (TDM) implementation phases (not yet implemented, partially implemented, fully implemented)
Trial: 33762226
Drug: Balanced energy-protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced energy-protein (BEP) supplement and iron/folic acid (IFA) tablets
Trial: 33762226
Drug: Iron/folic acid
RxNorm normalized name: iron/folic acid 150 mg-1 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron/folic acid (IFA) tablets only
Trial: 33762234
Drug: Pharmacist-led intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led intervention including physical and laboratory assessment, individualised CV risk assessment, education, treatment recommendations, prescription adaptation, regular communication with treating physician(s), and monthly follow-up for 6 months.
Trial: 33762322
Drug: Ad5 PSA/MUC-1/brachyury
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5 PSA/MUC-1/brachyury vaccine
Trial: 33762734
Drug: Vaccine targeting
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine targeting mutant IDH1
Trial: 33763241
Drug: Intrathecal rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intrathecal rituximab (20 mg, IT)
Trial: 33763241
Drug: Intravenous +
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous + Intrathecal (IV+IT)
Trial: 33763756
Drug: Emerging therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emerging therapies including post-neoadjuvant chemotherapy strategies, PARP inhibitors, immune checkpoint inhibitors, antibody-drug conjugates, and combination therapies (AKT/PI3K/mTOR-inhibitors, immunotherapeutic agents, CDK-inhibitors, antiandrogens, antiangiogenics, histone deacetylase inhibitors)
Trial: 33764309
Drug: Essential Coaching
RxNorm normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential Coaching for Every Mother program (text message program with 53 messages sent twice a day for the first 2 weeks and daily for weeks 3 through 6)
Trial: 33764552
Drug: Microneedle fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedle fractional radiofrequency treatment
Trial: 33764600
Drug: Sodium levofolinate
RxNorm normalized name: sodium levofolinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium levofolinate (Na-Lev) in combination with 5-fluorouracil (5-FU) administered in a single 48-hour pump
Trial: 33764600
Drug: Calcium levofolinate
RxNorm normalized name: calcium levofolinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium levofolinate (Ca-Lev) in combination with 5-fluorouracil (5-FU) with a 2-hour infusion
Trial: 33764809
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with CD19.28ζ-CAR T cells followed by alloHSCT
Trial: 33764812
Drug: Reasons for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reasons for missing medications
Trial: 33764991
Drug: Conventional obesity
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional obesity treatment (control group)
Trial: 33765041
Drug: GlycA (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GlycA (mean plasma level 381 μmol/L)
Trial: 33765164
Drug: Adjuvant therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapies (tyrosine kinase inhibitors or mTOR inhibitor)
Trial: 33765419
Drug: Iptacopan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iptacopan (200 mg twice daily)
Trial: 33765926
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NGS panel with AFP (20 ng/mL)
Trial: 33766502
Drug: Dose-escalated tumour
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated tumour boost radiotherapy
Trial: 33766844
Drug: Community delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community delivery of intermittent preventive treatment (C-IPTp) with sulfadoxine-pyrimethamine at each scheduled antenatal care (ANC) visit.
Trial: 33767061
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of kidney replacement therapy (KRT)
Trial: 33767061
Drug: Delayed initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Delayed initiation of kidney replacement therapy (KRT)
Trial: 33767093
Drug: C5 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C5 inhibitors and daptomycin
Trial: 33767093
Drug: Early antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early antibiotics
Trial: 33767648
Drug: iACTwithPain intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iACTwithPain intervention (eight weekly self-management sessions)
Trial: 33768419
Drug: Cemiplimab 350
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 350 mg Q3W
Trial: 33768419
Drug: Cemiplimab 3
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 3 mg/kg Q2W
Trial: 33769355
Drug: Saroglitazar 4
RxNorm normalized name: Saroglitazar 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saroglitazar 4 mg daily for 16 weeks
Trial: 33769497
Drug: Apatinib, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib, an anti-angiogenic tyrosine kinase inhibitor, administered once daily until disease progression, unmanageable toxicity, withdrawal, or death.
Trial: 33770527
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of Daily Living (ADL)
Trial: 33770575
Drug: Palbociclib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib (125 mg orally on days 1-21 of a 28-day cycle)
Trial: 33771853
Drug: Evofosfamide (400-640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evofosfamide (400-640 mg/m2) in combination with Ipilimumab
Trial: 33772397
Drug: Intraoral neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoral neuromuscular stimulation device (NMES), used for 20 min once daily for a 6-week period.
Trial: 33772428
Drug: Antithrombotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic treatment (including Factor Xa inhibitors/direct thrombin inhibitors and antiplatelet therapy)
Trial: 33772428
Drug: Factor Xa
RxNorm normalized name: Anti factor Xa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factor Xa inhibitors/direct thrombin inhibitors
Trial: 33774767
Drug: TAS0728 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS0728 at 200 mg BID
Trial: 33774767
Drug: TAS0728 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS0728 at 150 mg BID
Trial: 33774767
Drug: TAS0728 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAS0728 treatment response
Trial: 33775123
Drug: Vascular endothelial
RxNorm normalized name: Vascular endothelial growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vascular endothelial growth factor receptor inhibition
Trial: 33775523
Drug: Galsulfase enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galsulfase enzyme replacement therapy (ERT)
Trial: 33776633
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment group (6 months treatment)
Trial: 33778911
Drug: Independence in
RxNorm normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Independence in activities of daily living (ADL)
Trial: 33778928
Drug: Etrolizumab autoinjector
RxNorm normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrolizumab autoinjector (AI) 105 mg
Trial: 33780567
Drug: Single-dose, long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose, long-acting intravenous dalbavancin
Trial: 37118803
Drug: Furmonertinib 80
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furmonertinib 80 mg orally once daily
Trial: 33781934
Drug: Scoring tool
RxNorm normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scoring tool for systemic symptoms during aspirin challenge
Trial: 33782211
Drug: Gamma Irradiation
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma Irradiation (GI) at a target dose of 50 kGy